Geoffrey Shapiro Honored with MSCO Distinguished Researcher Award
Dana-Farber Cancer Institute shared a post on LinkedIn:
“The Massachusetts Society of Clinical Oncologists (MSCO) Board of Directors has honored Geoffrey Shapiro, with this year’s MSCO Distinguished Researcher Award.
He was bestowed with this prestigious award and featured as the keynote speaker during the MSCO Annual Dinner Meeting on Friday, December 13th.
Congratulations, Dr. Shapiro, on this notable recognition!”
Dr. Geoffrey Shapiro is a leading oncologist and the Director of the Early Drug Development Center at Dana-Farber Cancer Institute in Boston, where he has spent over 17 years advancing early-phase clinical trials for novel anti-cancer therapies.
His work focuses on first-in-human studies and proof-of-concept trials aimed at disrupting key biological pathways in cancer, such as signal transduction, angiogenesis, and DNA repair.
Additionally, Dr. Shapiro is deeply involved in exploring drug combinations that modulate the immune microenvironment in conjunction with immune checkpoint blockade.
With a medical degree and a Ph.D. in molecular biology and virology from Weill Cornell Medical College, Dr. Shapiro has dedicated his career to translating cutting-edge scientific discoveries into clinical treatments that improve outcomes for cancer patients.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023